Figure 7.

Evaluation of different anti-CTLA-4 combination therapies on EMT-6/P tumour growth. (A) Murine EMT-6/P cells were implanted s.c. into female Balb/c mice (n=7 per group). The mice received control saline (i.p.), anti-CTLA-4, or anti-CTLA-4 followed by second-line therapy consisting of gemcitabine (160 mg kg⁻¹ every 3 days, i.p.; CTLA-4 then gem), or anti-CTLA-4 therapy given concomitantly to gemcitabine therapy (CTLA-4+gem). In addition, one group received anti-CTLA-4 followed by second-line therapy consisting of CTX (20 mg kg⁻¹ day⁻¹, p.o.; CTLA-4 then CTX) or anti-CTLA-4 therapy with concomitant CTX therapy (CTLA-4+CTX). The results show that gemcitabine is a more effective therapeutic partner for anti-CTLA-4 than CTX, irrespective of whether the administration of gemcitabine is sequential or concomitant to the anti-CTLA-4. *P<0.05 vs control, ^#P<0.05 vs CTLA-4 then gem (mean values±s.d.). (B) Mouse weights, as a measure of toxicity of the different treatments.